NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Tuesday that several US clinical laboratories will adopt the company's breast cancer assay starting in the first quarter of 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.